| scholarly article | Q13442814 |
| P50 | author | Dominick Angiolillo | Q72837721 |
| P2093 | author name string | Fabiana Rollini | |
| Francesco Franchi | |||
| Jose R Rivas Rios | |||
| P2860 | cites work | Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). | Q51562214 |
| Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. | Q53359026 | ||
| Platelet aggregation in obese and diabetic subjects: association with leptin level. | Q53565307 | ||
| Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. | Q53944880 | ||
| Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. | Q54704923 | ||
| 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS | Q57621041 | ||
| Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | Q57764459 | ||
| Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | Q57764478 | ||
| Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Q57764490 | ||
| Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications | Q58329679 | ||
| Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus | Q60547969 | ||
| Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. | Q60924221 | ||
| Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy | Q62977698 | ||
| Platelet insulin receptor | Q67582366 | ||
| Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins | Q67956034 | ||
| Effects of insulin on calcium metabolism and platelet aggregation | Q71258054 | ||
| Platelets from diabetic subjects show diminished sensitivity to prostacyclin | Q71634275 | ||
| Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria | Q71938783 | ||
| ADP receptors of platelets and their inhibition | Q74314926 | ||
| Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein | Q77636152 | ||
| Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects | Q79383025 | ||
| Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study | Q79685552 | ||
| Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood | Q79774080 | ||
| Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis | Q80550892 | ||
| Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis | Q80607346 | ||
| Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway | Q81163093 | ||
| Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo") | Q83541230 | ||
| Pharmacogenetics in cardiovascular antithrombotic therapy | Q84541445 | ||
| Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus | Q84561624 | ||
| Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies | Q85036168 | ||
| Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease | Q85253139 | ||
| Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI | Q87274514 | ||
| 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Q89104948 | ||
| Diagnosis and Classification of Diabetes Mellitus | Q22255454 | ||
| Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart | Q24311811 | ||
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | Q24645391 | ||
| Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials | Q26785723 | ||
| Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence | Q26799079 | ||
| Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials | Q26852886 | ||
| Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study | Q28165115 | ||
| Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes | Q28167317 | ||
| Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention | Q28168588 | ||
| Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood | Q28190630 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Low-dose aspirin for the prevention of atherothrombosis | Q28193680 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment | Q28199546 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin | Q28219365 | ||
| The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study | Q28221353 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease | Q28222643 | ||
| Regulation of platelet plasma membrane Ca2+-ATPase by cAMP-dependent and tyrosine phosphorylation | Q28240515 | ||
| Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 | ||
| Global and societal implications of the diabetes epidemic | Q29614551 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study | Q33333456 | ||
| Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow | Q39586331 | ||
| Prasugrel versus clopidogrel for acute coronary syndromes without revascularization | Q40058838 | ||
| Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people | Q40108176 | ||
| Long-term use of ticagrelor in patients with prior myocardial infarction | Q40263764 | ||
| Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial | Q40759916 | ||
| Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. | Q40817339 | ||
| Insulin, insulin resistance, and platelet signaling in diabetes | Q41951212 | ||
| Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. | Q42453569 | ||
| Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production | Q42468613 | ||
| Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes | Q42917068 | ||
| Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function | Q43264426 | ||
| Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. | Q43554882 | ||
| Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium | Q43566887 | ||
| Platelet antioxidant enzymes in insulin-dependent diabetes mellitus | Q43641231 | ||
| Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar | Q44056270 | ||
| IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi | Q44645484 | ||
| Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus | Q44668369 | ||
| Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes | Q44754180 | ||
| Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease | Q44938343 | ||
| Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. | Q45045640 | ||
| Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo | Q46214428 | ||
| Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease | Q46418067 | ||
| A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. | Q46528728 | ||
| Platelet inhibition by insulin is absent in type 2 diabetes mellitus | Q46843983 | ||
| Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone | Q46856893 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy | Q47757284 | ||
| The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts | Q47865745 | ||
| Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus | Q47992848 | ||
| Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. | Q50573978 | ||
| Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. | Q51446902 | ||
| Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. | Q51496269 | ||
| Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention | Q33613297 | ||
| Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study | Q34021458 | ||
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes | Q34231934 | ||
| Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 | ||
| Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. | Q34389439 | ||
| Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial | Q34404150 | ||
| A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial | Q34751965 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Atherothrombosis, inflammation, and diabetes | Q35101130 | ||
| Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial | Q35195203 | ||
| Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis | Q35200308 | ||
| Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. | Q35540861 | ||
| Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. | Q35546626 | ||
| Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 | ||
| Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
| Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding | Q36308327 | ||
| Effects of VLDL and remnant particles on platelets | Q36551304 | ||
| Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes | Q37022618 | ||
| Oxidative stress and platelets | Q37049876 | ||
| Factors contributing to increased platelet reactivity in people with diabetes | Q37139534 | ||
| Platelet thrombin receptor antagonism and atherothrombosis | Q37641556 | ||
| Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans | Q37641606 | ||
| Diabetes and antiplatelet therapy in acute coronary syndrome. | Q37846051 | ||
| Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease | Q38020865 | ||
| The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. | Q38053481 | ||
| Platelet function profiles in patients with diabetes mellitus | Q38081078 | ||
| Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance | Q38207389 | ||
| Novel antiplatelet agents in acute coronary syndrome | Q38257119 | ||
| Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention | Q38378830 | ||
| Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study | Q38388438 | ||
| Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study | Q38394612 | ||
| Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside | Q38402334 | ||
| Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease | Q38493656 | ||
| Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections | Q39474763 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 594-609 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Cardiovascular diagnosis and therapy | Q26842243 |
| P1476 | title | Diabetes and antiplatelet therapy: from bench to bedside. | |
| P478 | volume | 8 |
| Q89712805 | Alteration of purinergic signaling in diabetes: Focus on vascular function |
| Q64277113 | Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes |
| Q92476250 | Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels |
| Q97682139 | Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry |
| Q90666020 | Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients |
| Q92328545 | Coagulatory Defects in Type-1 and Type-2 Diabetes |
| Q93018504 | Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review |
Search more.